UNION KOREA PHARM: Capital Increase via Debt-to-Equity
한국유니온제약
080720
Signal Score
Historical Avg Return (5d)
+0.26%
Data Coverage
100%n=2457
Risk-adjusted indicator based on 2457 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Court Approval Date: May 12, 2026
- • Debt-to-Equity Conversion Effective Date: May 19, 2026
- • Capital Reduction (Merger) Effective Date: May 27, 2026
- • Third-Party Allotment Capital Increase Effective Date: May 28, 2026
AI Analysis Summary
UNION KOREA PHARM CO.,Ltd received court approval for its rehabilitation plan on May 12, 2026. The company will proceed with a debt-to-equity conversion effective May 19, 2026, followed by a capital reduction on May 27, 2026, and a third-party allotment capital increase on May 28, 2026. This capital increase is primarily for debt repayment through equity conversion, with no new cash contributions. The maximum shareholder dilution rate is not specified but the largest shareholder is expected to change. The overall impact is neutral as it's part of a court-mandated rehabilitation plan.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.